Initial combination therapy with ambrisentan+tadalafil on pulmonary arterial hypertension-related hospitalization in the ambition trial
In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) versus pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination therapy group, though a significant effect was not observed in a post-hoc analysis of all-cause hospitalization.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Jean-Luc Vachi éry, Nazzareno Galiè, Joan Albert Barberá, Adaani E Frost, Hossein-Ardeschir Ghofrani, Marius M Hoeper, Vallerie V McLaughlin, Andrew J Peacock, Gérald Simonneau, Christiana Blair, Karen L. Miller, Jonathan Langley, Lewis J Rubin, for t Tags: Original Clinical Science Source Type: research
More News: Cardiology | Cialis | Heart | Heart Transplant | Hypertension | Lung Transplant | Science | Study | Transplants